Business description
Illumina is improving human health by unlocking the power of the genome. The company's focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Illumina's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.
Management board & Supervisory board
| CEO |
| Francis deSouza |
| Management board |
| Aimee Hoyt, Charles Dadswell, Dr. Alex Aravanis, Dr. Joydeep Goswami, Dr. Phil Febbo, Gretchen Weightman, Kathryne Reeves, Kevin Pegels, Li Qing, Nicole Berry, Paula Dowdy, Salli Schwartz, Susan Tousi |
| Supervisory board |
| John W. Thompson, Caroline Dorsa, Dr. Frances Arnold, Francis A. deSouza, Gary S. Guthart, Philip W. Schiller, Robert S. Epstein, Scott Gottlieb, Susan E. Siegel |
Company data
| Name: |
Illumina Inc. |
| Address: |
5200 Illumina Way,San Diego, California 92122, USA |
| Phone: |
+1-858-202-4500 |
| Fax: |
+1-858-202-4545 |
| E-mail: |
info@illumina.com
|
| Internet: |
www.illumina.com/ |
| Industry: |
Healthcare |
| Sector: |
Medical Products |
| Sub sector: |
Advanced Medical Devices |
| End of financial year: |
12/31 |
| Free Float: |
66.10% |
| IPO date: |
- |
Investor relations
| Name: |
Juliet Cunningham |
| IR phone: |
+1-858-882-2172 |
| IR Fax: |
- |
| IR e-mail: |
ir@illumina.com
|